Day 1 - July 19, 2022: BioProcess Insider Focus
BioProcess Insider Panel Discussion — Recombinant Protein Manufacturing: Lessons to Be Taken from the Emerging Cell and Gene Therapy Space
11:00 AM ET — David Chang, CEO, WuXi Advanced Therapies; Neal Gordon, Managing Director, BPTG, BDO USA; and Christopher Peterson, Associate Director, Strategic Consultant, Latham BioPharm Group
Tech R&D investments are increasingly looking to tackle issues in cell and gene therapy manufacturing, but is this to the detriment of the wider biomanufacturing space? This panel will discuss whether bioprocess innovation has stalled for 'tried and tested' biologics and whether technologies and processes being investigated in the advanced therapy space can and will be implemented for more traditional modalities.
BioProcess Insider Interviews
11:45 AM ET — Tom VanCott, PhD, Global Head of Product Development, Catalent
11:55 AM ET — Martin Meeson, CEO, FUJIFILM Diosynth Biotechnologies
12:05 PM ET — Claudia Melara, VP Key Accounts, Gamma Biosciences
12:15 PM ET — James Park, Executive Vice President, Samsung Biologics
12:25 PM ET — Brian Finrow, Co-founder & CEO, Lumen Biosciences
12:35 PM ET — Dr. Ger Brophy, Executive Vice President, Biopharma Production, Avantor
Day 2 - July 20, 2022: Emerging Therapies
Platform Processes Accelerating AAV Vector Production from Gene to Clinic
11:00 AM ET — Tom VanCott, PhD, Global Head of Product Development, Catalent Cell and Gene Therapy
The cell and gene therapy market continues to grow rapidly, with new molecules entering clinical trials and many reaching late-stage clinical studies as life-changing therapies for previously untreatable diseases including monogenetic disorders, cancer, and infectious diseases. Adeno-associated viral (AAV) vectors are the primary vector used for the production of viral vector-based gene therapies. As demand for AAV vector manufacturing has grown, so too has the demand for plasmid DNA, a critical component to many advanced therapeutics. Some of the challenges facing cell and gene therapy manufacturing are scalability, the lack of advanced platform processes, and supply chain bottlenecks. During this talk, Catalent’s platform manufacturing processes for plasmid DNA and AAV vectors will be presented, including how they can address these challenges, support early activities, and facilitate the transition towards GMP production for clinical and commercial supply. Attendees will learn about:
- the features of plasmid and AAV platform processes
- the advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities
- how a platform manufacturing process can accelerate advanced therapies from gene to clinic.
Building a Comprehensive Toolbox for Oligonucleotide Drug Discovery
11:20 AM ET — Dave Madge, Vice President, WuXi AppTec
Recent years have seen tremendous progress in the application of RNA/DNA-based therapeutics, with successful treatments reaching the market and the potential for widespread applications becoming a realizable objective. In parallel the diversity of application of this modality is rapidly expanding to encompass not just gene silencing but also splice modulation and gene activation, as well as demonstrating potential to target patient-specific sequences that are causative for rare diseases. We are committed to helping diverse research teams achieve the full potential of oligonucleotide therapeutics and have been diligently building a comprehensive platform to support this.
The Future of AAV Gene Therapy Is Scalable
11:40 AM ET — Dr. Ryan Cawood, Chief Scientific Officer, WuXi Advanced Therapies
The gene therapy industry is fueled by the desire to expand patient access to these novel, and potentially life-saving, treatments. However, for these treatments to become widely available, manufacturing technologies must keep pace with biological advances and offer robust, scalable, and reliable platforms for cost-effective AAV production.
Here, we demonstrate that our proprietary plasmid-free TESSA™ technology is fully scalable, delivering high titer (over 7E11 GC/mL), exceptional packaging efficiencies (94% by analytical ultracentrifugation post purification), and high infectivity (1.4E11 infectious units/mL) when used to manufacture AAV6 at 50L scale.BioProcess Insider Panel Discussion — Therapeutic Cell and Gene Therapy Modalities: Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type Versus Another
12:00 PM ET — Patricia Seymour, Managing Director BPTG, BDO USA, Justin Skoble, Vice President of Technical Operations, Caribou Biosciences, Inc.; Adam Fowler, SVP TO, Locana Bio; and Eytan Abraham, VP Head of Cell Therapy, National Resilience
Industry experts discuss different cell and gene therapy modalities to treat various diseases, their unique manufacturing challenges, and appropriate strategy decisions including:
- manufacturability
- access to manufacturing capacity — outsource or build?
- how prevalent will these therapies will be by 2025?
Enabling Next-Generation Biomanufacturing Using Cell-Free Technology
12:45 PM ET — Weston Kightlinger, PhD, Director, Cell-Free Protein Synthesis, National Resilience
In recent years, new therapeutic formats with increasing structural complexity, diversity, and novelty have emerged. These new formats exceed the capabilities and agility of existing biologics host cell lines and manufacturing methods. Limitations include low volumetric productivities due to cell propagation in fed-batch bioreactors, the time required to develop unique processes and cell lines for each new therapeutic, insufficient flexibility and control over post-translational modifications including disulfide bonds and glycosylation, and difficulties in producing and secreting new-to-biotech or even new-to-nature protein folds and structures due to balancing cellular viability and therapeutic production. In this presentation, Weston will discuss how Resilience’s next-generation biomanufacturing capabilities overcome these key bottlenecks and highlight its cell free protein synthesis platform. Resilience’s platform provides direct control over the protein synthesis environment in an in vitro coupled transcription-translation reaction that generates high titers of complex proteins from a DNA template in less than a day. He will also describe how Resilience is leveraging the flexibility of its cell-free technology as well as process development and manufacturing infrastructure to unlock the potential of protein therapeutics that are difficult or impossible to manufacture by other means. Taken together, these advancements in the science of biopharmaceutical manufacturing and development free our partners to focus on the discoveries that improve patients’ lives.Innovation as the Key to GT Manufacturing
1:05 PM ET — David Backer, Chief Commercial Officer, Oxford Biomedica
While gene therapy remains a relatively new therapeutic modality, expected improvements similar to those seen in the monoclonal antibody space have largely not occurred. We will discuss the importance of continued innovations for viral vectors, concentrating on efforts made in Oxford Biomedica’s lentivirus template process, as well as AAV productivity and purity results recently announced at the company’s newly-formed, Boston based company, Oxford Biomedica Solutions.
How a Robust, Fully-Integrated and Highly-Vetted Cell Line Development Platform Enables Record Breaking DNA to IND Timelines
1:25 PM ET — Sherry Gu, PhD, SVP of CMC Management, WuXi Biologics
Partnering with a CDMO: Past the Service Offering
1:45 PM ET — Elie Hanania, PhD, Vice President, Process Development Viral Vector Technologies, Avid Bioservices
Progress in the gene and cell therapy, coupled with positive outcomes of many clinical trials based on advanced therapies heightened the demand for contract development and manufacturing organizations (CDMOs). It is imperative to consider a partnership with these entities and not a fee-for-service transaction. Clients naturally focus on the available capacity when selecting a CDMO partner. Other crucial qualities that tend to be overlooked during CDMO searches such as the technical capability, quality systems, and regulatory track records, should be pivotal considerations when selecting a long term CDMO partner. An effective CDMO search should result in a partner that has available capacity, state-of-the art technologies, skilled resources, proven quality systems, significant GMP manufacturing experience, flexible business approaches, and a secure financial position to truly support their clients in producing life-saving advanced gene and cell therapies.
Accelerating the Industrialization of Genomic Medicine
2:05 PM ET — Clive Glover, General Manager, Gene Therapy, Pall Corporation
As genomic medicine becomes a more and more important modality for treatment of disease, technologies to manufacture these therapies in a safe and consistent fashion has become more and more important. This talk will review the current state of manufacturing for these important therapies and highlight the importance of innovation in the field.
Overcome Costly Hit-Finding Challenges: Integrated Platform for Success
2:25 PM ET — Thomas Meins, Global Head, Protein Production, HitS, WuXi AppTec
Drug discovery programs are empowered with a comprehensive, integrated platform offering high-quality protein in combination with other well-established capabilities including target validation, hit finding (fragment, compound, or DNA Encoded Library screenings) and hit confirmation (biophysics, biochemistry). Importantly, WuXi AppTec provides our partner clients the ability to obtain structural elucidation of their target at atomic precision from X-ray crystallography, cryo-EM, or NMR.
How a Premier Single Source Platform Accelerates Biologic Drug Discovery and Innovation
2:45 PM ET — Jijie Gu, PhD, Chief Scientific Officer, WuXi Biologics
As a leading CRDMO, WuXi Biologics offers end-to-end solutions to enable global partners to discover, develop, and manufacture biologics. Our full spectrum of cutting-edge technologies and highly efficient one-stop discovery services provides multiple integrated platforms from target identification to final lead candidate selection for antibody generation, protein engineering, lead selection, lead optimization, characterization and production. We bring industry-leading expertise and experience to help our clients to achieve their goals in finding monoclonal, bispecific, and multispecific antibody therapeutics, antibody-drug conjugates, engineered cytokines, and other protein therapeutics with desired functional properties. Our state-of-the-art facilities can meet any needs for high yield, high-speed protein production at any scale using a variety of expression systems. Our approach to biologics discovery includes our efficient one-stop ADC platform, with services ranging from target selection, antibody generation, linker and payload conjugation, in vitro and in vivo biological and physiochemical characterization, and CMC development all the way to commercial manufacturing. In the past decade we have successfully enabled our clients to not only discover antibody lead candidate therapeutics starting from therapeutic concept, but also to integrate discovery with CMC development to provide a highly efficient target to commercialization platform that leads to regulatory approval.
BioProcess Insider interviews
3:05 PM ET — Dave Backer, Chief Commercial Officer, Oxford Biomedica
3:15 PM ET — Jon Gunther, VP, Business Development, Just – Evotec Biologics
Day 3 - July 21, 2022: Emerging Techniques, Technologies, and Strategies
Shortening Clinical Developments Timeline Using Novel GPEx® Lightning Technology for Generating Stable, High-Producing Cell Pools and Cell Lines
11:00 AM ET — Greg Bleck, PhD, Vice President of Research and Development, Catalent
Speed and efficiency remain major drivers for developers bringing their protein-based biologics to first-in-human studies. For 20 years, GPEx® cell line development technology has provided a proven approach to generate high-expressing, highly stable mammalian cell lines, with 16 commercially approved biologics that have been developed to date. Building off the synergies of GPEx® technology, a glutamine-synthetase knockout, targeted gene insertion and two proprietary concepts, Catalent recently introduced GPEx Lightning, a fast, flexible way to shorten the path to production of cGMP product. During this talk, we share the latest data leveraging GPEx® Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx® suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials. Attendees will learn about:
- latest updates to the GPEx® suite of technologies developed by Catalent
- accelerated timeline by GPEx® Lightning to generate biotherapeutics for first-in-human studies
- performance of GPEx® Lightning on generating stable cell pools and cell line.
Using Innovation and Investments to Advance Nanoparticle Formulations
11:20 AM ET — Tara Lorenz, Director, Commercial Development, Emergent BioSolutions
With the use of lipid nanoparticles (LNPs) in recent COVID-19 mRNA vaccines, nanoparticle formulations have gained increasing attention as an effective drug delivery system for a variety of complex active pharmaceutical ingredients (APIs), including for applications in immuno-oncology, gene therapy, and vaccine products. With considerable experience in the development and manufacturing of lipid-based formulations, Emergent CDMO has been advancing its capabilities and expertise to include nanoparticle formulations. Through recent investments in infrastructure and equipment, Emergent CDMO is prepared to meet current and future industry-wide demand for nanoparticle formulations from pre-clinical to commercial production.
Improvements and Innovations in Lentiviral Manufacture
11:40 AM ET — Dr. Ryan Cawood, Chief Scientific Officer, WuXi Advanced Therapies
Lentiviral vectors are safe and efficient gene transfer tools for cell therapies and are often required at high titers; however, robust and cost-effective large-scale vector production remains challenging.
Here we describe WuXi Advanced Therapies’ XLenti suspension platform, which uses a high-producing HEK293 clonal cell line, OXGENE's XLenti™ packaging plasmids, and carefully optimized up- and downstream processes that can deliver titers up to 1E8 TU/mL and can be scaled up to 200 L. In-house plasmid engineering and antibiotic free plasmid manufacture at research and GMP grade further simplifies technology transfer and accelerates development timescales for lentiviral-based cell or gene therapies. Finally, for plasmid-free lentiviral vector production, our lentiviral producer cell lines incorporate all the genetic elements from the XLenti plasmid system alongside the gene of interest and produce equivalent lentiviral yields to the transient system.
BioProcess Insider Panel Discussion — Therapeutic Cell and Gene Therapy: Introducing New Technologies to Compress Timelines, Increase Capacity and Reduce Risk
12:00 PM ET — Nicholas Vrolijk, Managing Director, BPTG, BDO USA; Edwin Beale, Vice President, iVEXSol; David Chang, CEO, WuXi Advanced Therapies; and Bruce Thompson, VP and Technical Lead Cell, National Resilience
SymphonXTM: Advancing Biomanufacturing Capabilities with a Next-Generation Single-Use Technology Solution
12:45 PM ET — Dr. Charles Heise, Senior Staff Scientist, Bioprocessing Strategy & Development Group, FUJIFILM Diosynth Technologies
The in-house developed downstream purification system SymphonXTM uses a disposable, generic flow path to operate multiple downstream process unit operations (e.g. chromatography, tangential flow filtration (TFF), single-pass TFF, viral inactivation and viral filtration). This presentation outlines the functional flexibility of the system, its advanced buffer management capabilities (in-line conditioning and in-line dilution) and operational capability improvements. The SymphonX™ design simplifies the single-use consumable supply chain, allows plug and play flexibility across all downstream unit operations and provides a generic operator interface to de-risk execution of complex batch and continuous bioprocessing operations in a multi-product facility.
Rapid Screening of Bioavailability Enhancing Technologies to Accelerate Time to Clinic
1:05 PM ET — Jesus Rosales, Sr. Scientist, Oral Formulation Development, Catalent
There is increasing pressure to improve the productivity and efficiency of the drug development process. This often translates to accelerating formulation development timelines with limited data or material. However, there are API sparing analytical tools available that can help with the assessment of physicochemical properties of the API that can guide the selection of formulation approaches to mitigate various oral bioavailability liabilities of the drug. Technologies such as amorphous solid dispersions, lipid formulations, and particle size reduction can be powerful tools when employed early in the development stages. A scientific expert from Catalent will provide insight into how to navigate issues relating to oral product development and address these challenges early for a successful outcome in preclinical and early-stage clinical studies.
Key learning objectives:
- Understand how API sparing techniques can help select the right formulation platform technologies.
- Discover the rapid pathway of prototyping to fast track in vitro and in vivo studies.
- Learn how to incorporate rapid formulation technology screening into the overall early drug development strategy.
How Our Partnerships Move Your Life-Changing Biologics to Market: Two Case Studies
1:25 PM ET — Muctarr Sesay, PhD, Chief Scientific Officer, Goodwin Biotechnology
This 20-minute presentation will include:- A brief overview and capabilities of Goodwin Biotechnology Inc., focusing on the development and manufacturing of complex biologics.
- Presentation of two case studies demonstrating how Goodwin successfully overcame serious challenges with CMC aspects of the client’s product, ensuring they successfully proceeded in the clinic from early stage to late-stage trials. One of these products is planned to be part of a BLA filing in the US within the next twelve months:
- Novel bioconjugation development process for aggregate removal and successful cGMP manufacturing of a complex biologic theranostic molecule for a global biopharmaceutical company in late-stage trials.
- Process development and scale-up cGMP manufacturing of conjugate vaccines for the treatment of opioid use disorders for clinical trials being conducted by a leading organization in this field.
- Ongoing/Future project opportunities
Crossing the Finish Line: Preparing for and Passing a Pre-Approval Inspection
1:45 PM ET — Ray Marzouk, Vice President, Quality, Avid Bioservices
You have spent years on research and development, manufactured several process validation lots, and worked months on authoring and filing your submission. You are ready to take your product to the commercial market, but do you and/or your manufacturing partner have what it takes to cross the finish line? In this presentation, you will learn how to prepare for a pre-approval inspection and how to effectively manage the inspection to ensure a successful outcome.
How Advanced Therapies are Changing the CDMO Landscape
2:05 PM ET — Dan Stanton, Co-founder and Editor, BioProcess Insider
Cell therapies continue to be blighted by CMC complexities and bottlenecks; demand for viral vector production continues to outweigh supply. Increased investment in mRNA requires increased expertise to bring vaccines and therapies to market. This talk will assess how the CDMO sector has rallied to resolve these issues, what more can be done, and how new investments and companies entering the space are shaking up the dynamics in the sector.
BioProcess Insider Interviews
2:25 PM ET — Emmanuel Ligner, President and CEO, Cytiva
2:35 PM ET — Greg Bleck, PhD, Vice President of Research and Development, Catalent

